Clinical trials / NCT-BPC402-101

phase 1 · Completed

Phase 1 dose escalation of BPC-402 in EGFR-mutant NSCLC

First-in-human dose escalation of BPC-402, an anti-HER3 antibody-drug conjugate, in EGFR-mutant non-small cell lung cancer after EGFR tyrosine kinase inhibitor therapy.

BPC-402 Sample data

Investigational candidate. BPC-402 has not been approved by any regulatory authority.

Enrollment

Patient participation.

Enrolled 40
Target 40
Sites 3

100% of target enrollment reached.

Design

Trial endpoints.

Primary endpoint

Safety and recommended Phase 2 dose.

Secondary endpoints

  • Pharmacokinetics
  • Objective response rate

Eligibility

Adults with EGFR-mutant NSCLC and disease progression on an EGFR TKI.

Timeline

Started
June 1, 2022
Ended
December 1, 2023

Sites

3 sites for NCT-BPC402-101.

  • Cambridge Research Center

    245 Binney Street, Cambridge, MA 02142

    Cambridge, United States

  • Texas Cancer Institute

    1515 Holcombe Boulevard, Houston, TX 77030

    Houston, United States

  • National Tokyo Medical Center

    2-1-21 Higashigaoka, Meguro-ku, Tokyo 152-0021

    Tokyo, Japan
Back to trials View BPC-402